Finzati - Logo
PPCB logo

Propanc Biopharma, Inc.

PPCBBiotechnology
$1.01
-0.01 (-0.98%)
Current price
EarningsLatest report: Mar 31, 2026
HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology
Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.
Market Cap
$906,069.99
Growth
Cash Flow
0/5
Trend
Negative
Evidence
Manageable debt level · 0.12Healthy liquidity · 1.5Weak profitability
Financial data as of: Mar 31, 2026, 12:00 AM UTCLast earnings update: May 14, 2026, 12:00 AM UTCLast profile update: Aug 5, 2026, 2:27 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$1.01
Change-0.98%
Shares Out897.10K
Market Cap$906.07K
Enterprise Value$2.01M
Beta3.29
P/E-0.05
P/B0.09
P/FCF-0.22
EV/EBITDA-0.11
EV/FCF-0.49
FCF Yield-453.96%

Investment DNA

How strong this company looks for long-term investors

47
out of 100
Business Quality
Margins, moat, returns
22/100
Financial Strength
Debt, cash, stability
72/100
Growth Potential
Revenue and expansion
50/100
Price Attractiveness
Cheap or expensive today
93/100
Why this score
Manageable debt level · 0.12Healthy liquidity · 1.5Weak profitability
Analyst view
No analyst data available now.

Company Overview

IPO: 11/12/2012
Industry: Biotechnology
P/B i: 0.09
Debt / Equity i: 0.12
Operating Margin: 0.00%
Net Margin: 0.00%
ROE i: -
ROIC: -

Financial Health

Score14 / 20
Debt / Equity: 0.12
Current Ratio: 1.50
Quick Ratio: 1.50
Status: Good

Insider Transactions

Recent executive and insider activity

2 high-volume insider sells detected
ZELINGER JOSEF
Transaction: 07/05/2023
BUY
Change
+15,000,000
Price
$0.01
Filing
08/23/2023
Type
BUY
ZELINGER JOSEF
Transaction: 08/17/2021
SELL
Change
0
Price
Not reported
Filing
08/20/2021
Type
SELL
Nathanielsz James Andrew
Transaction: 08/17/2021
BUY
Change
+2,800,000
Price
Not reported
Filing
08/20/2021
Type
BUY